Contract research, development, and manufacturing services organisation Aurigene Pharmaceutical Services has decided to establish a state-of-the-art development and manufacturing facility focusd on niche areas like therapeutic proteins, antibodies and viral vectors in Genome Valley, Hyderabad.

A step-down subsidiary of pharma major Dr.Reddy’s Laboratories, it intends to invest $40 million (around 330 crore), which will be generating around 200 direct jobs and 60-70 indirect employment opportunities over the next three years. The announcement from Industries and IT Minister K.T.Rama Rao’s office came after CEO Akhil Ravi and Dr.Reddy’s chairman Satish Reddy met and briefed him about the company’s plan on Tuesday.

“Delighted Aurigene has chosen Genome Valley to establish their R&D and manufacturing facility. The investment is aligned perfectly with the government’s vision to enhance complex manufacturing at scale by investing in biotherapeutics discovery, Aurigene has further strengthened Hyderabad’s position as a preferred destination for biopharmaceutical research and production,” Mr.Rama Rao said in a release.

Aurigene said it envisions significant scaling-up of the investments in future, which would result in a multi-fold increase in employment prospects in very advanced science and manufacturing technologies. It would be collaborating with globally leading biotech innovators to facilitate development and introduction of innovative medicines into the market.